Alys Pharmaceuticals has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi. The company originates from the aggregation of six Medicxi companies. Co-founded by Medicxi and several dermatology and scientific experts, including John Harris (UMass Chan Medical School), Brian Kim (Icahn School of Medicine at Mount Sinai), […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!